Bradfield Scott M, Douglas James G, Hawkins Douglas S, Sanders Jean E, Park Julie R
Department of Pediatric Hematology/Oncology, Children's Hospital and Regional Medical Center, Seattle, Washington 98105-5371, USA.
Cancer. 2004 Mar 15;100(6):1268-75. doi: 10.1002/cncr.20091.
The optimal administration of radiotherapy for patients with high-risk neuroblastoma (NB) currently is undefined in the context of modern therapy using myeloablative chemotherapy with autologous stem cell rescue (hematopoietic stem cell transplantation [HSCT]).
The authors conducted a retrospective review of the records of 21 consecutive patients with high-risk NB to assess local control and toxicity of external beam radiotherapy (XRT). Therapy included multiagent induction chemotherapy and delayed surgical resection, consolidation of HSCT and local XRT, and 13-cis-retinoic acid maintenance therapy. XRT was delivered to the primary site, using postchemotherapy volumes, and to initial metastatic sites with 1-2 cm margins to 2100 centigrays (cGy) using 14 fractions administered once daily.
Four of 21 patients did not receive XRT due to toxic death (n = 2), disease progression before XRT (n = 1), or parental refusal (n = 1). The median time to XRT post-HSCT was 54 days. Thirteen patients received a second peripheral blood stem cell infusion after completing XRT. Twelve of the 14 patients who received XRT post-HSCT and for whom toxicity data were available had Grade 3-4 acute toxicities, including gastrointestinal toxicity (n = 8), hematologic toxicity (n = 9), and infection (n = 1). Nonrecurrent long-term toxicities included prolonged nutritional deficiency (n = 9) and leg-length discrepancy (n = 1). Tumors recurred in 7 of 21 patients (5 of 17 patients who received radiotherapy), either within a radiation field (n = 1) or at distant nonirradiated sites (n = 6). The estimated local failure rate was 7% (95% confidence interval [95% CI], 0-14%), with a 2-year event-free survival rate of 48% (95% CI, 26-70%).
Post-HSCT, fractionated XRT to 2100 cGy was a tolerable and effective treatment for patients with high-risk NB, and minimal recurrences were observed at designated XRT sites.
在采用清髓性化疗联合自体干细胞救援(造血干细胞移植[HSCT])的现代治疗背景下,高危神经母细胞瘤(NB)患者的最佳放疗方案目前尚不明确。
作者对21例连续的高危NB患者的记录进行了回顾性分析,以评估外照射放疗(XRT)的局部控制情况和毒性。治疗包括多药诱导化疗和延迟手术切除、HSCT巩固和局部XRT以及13 - 顺式维甲酸维持治疗。XRT应用化疗后靶区体积照射原发部位,并对初始转移部位外放1 - 2 cm边界,每天一次,分14次给予2100厘戈瑞(cGy)。
21例患者中有4例未接受XRT,原因分别为毒性死亡(n = 2)、XRT前疾病进展(n = 1)或家长拒绝(n = 1)。HSCT后至XRT的中位时间为54天。13例患者在完成XRT后接受了第二次外周血干细胞输注。在14例HSCT后接受XRT且有毒性数据的患者中,12例出现3 - 4级急性毒性反应,包括胃肠道毒性(n = 8)、血液学毒性(n = 9)和感染(n = 1)。非复发性长期毒性反应包括长期营养缺乏(n = 9)和腿长差异(n = 1)。21例患者中有7例复发(接受放疗的17例患者中有5例),其中1例在放疗野内复发,6例在远处未照射部位复发。估计局部失败率为7%(95%置信区间[95%CI],0 - 14%),2年无事件生存率为48%(95%CI,26 - 70%)。
HSCT后,分次给予2100 cGy的XRT对高危NB患者是一种可耐受且有效的治疗方法,并在指定的XRT部位观察到极少的复发情况。